1. Home
  2. CYTK vs BEP Comparison

CYTK vs BEP Comparison

Compare CYTK & BEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYTK
  • BEP
  • Stock Information
  • Founded
  • CYTK 1997
  • BEP 1999
  • Country
  • CYTK United States
  • BEP Canada
  • Employees
  • CYTK N/A
  • BEP N/A
  • Industry
  • CYTK Biotechnology: Pharmaceutical Preparations
  • BEP Electric Utilities: Central
  • Sector
  • CYTK Health Care
  • BEP Utilities
  • Exchange
  • CYTK Nasdaq
  • BEP Nasdaq
  • Market Cap
  • CYTK 5.6B
  • BEP 6.4B
  • IPO Year
  • CYTK 2004
  • BEP N/A
  • Fundamental
  • Price
  • CYTK $32.48
  • BEP $22.75
  • Analyst Decision
  • CYTK Buy
  • BEP Buy
  • Analyst Count
  • CYTK 19
  • BEP 7
  • Target Price
  • CYTK $77.33
  • BEP $29.00
  • AVG Volume (30 Days)
  • CYTK 2.4M
  • BEP 446.0K
  • Earning Date
  • CYTK 05-06-2025
  • BEP 05-02-2025
  • Dividend Yield
  • CYTK N/A
  • BEP 6.40%
  • EPS Growth
  • CYTK N/A
  • BEP N/A
  • EPS
  • CYTK N/A
  • BEP N/A
  • Revenue
  • CYTK $19,218,000.00
  • BEP $5,964,000,000.00
  • Revenue This Year
  • CYTK $55.84
  • BEP $14.36
  • Revenue Next Year
  • CYTK $646.96
  • BEP $6.18
  • P/E Ratio
  • CYTK N/A
  • BEP N/A
  • Revenue Growth
  • CYTK 412.21
  • BEP 14.71
  • 52 Week Low
  • CYTK $31.67
  • BEP $19.29
  • 52 Week High
  • CYTK $68.44
  • BEP $29.56
  • Technical
  • Relative Strength Index (RSI)
  • CYTK 31.23
  • BEP 55.01
  • Support Level
  • CYTK $34.88
  • BEP $22.17
  • Resistance Level
  • CYTK $43.51
  • BEP $23.59
  • Average True Range (ATR)
  • CYTK 2.00
  • BEP 0.56
  • MACD
  • CYTK -0.67
  • BEP 0.05
  • Stochastic Oscillator
  • CYTK 6.84
  • BEP 65.57

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About BEP Brookfield Renewable Partners L.P.

Brookfield Renewable is a globally diversified, multitechnology owner and operator of clean energy assets. The company's portfolio consists of hydroelectric, wind, solar, and storage facilities in North America, South America, Europe, and Asia and totals over 20 gigawatts of installed capacity. Brookfield Renewable invests in assets directly, as well as with institutional partners, joint venture partners, and through other arrangements. The company offers two separate listings for investors: Brookfield Renewable Partners and Brookfield Renewable Corp.

Share on Social Networks: